OLD Mission Capital LLC increased its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 8,813.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,087,798 shares of the company's stock after purchasing an additional 1,075,594 shares during the quarter. OLD Mission Capital LLC owned approximately 0.13% of Dr. Reddy's Laboratories worth $17,176,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC lifted its holdings in shares of Dr. Reddy's Laboratories by 423.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after buying an additional 1,507 shares in the last quarter. POM Investment Strategies LLC boosted its holdings in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after purchasing an additional 1,820 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of Dr. Reddy's Laboratories by 461.0% during the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock valued at $40,000 after purchasing an additional 2,093 shares in the last quarter. Independence Bank of Kentucky lifted its position in shares of Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company's stock worth $44,000 after buying an additional 2,220 shares in the last quarter. Finally, Allworth Financial LP boosted its stake in Dr. Reddy's Laboratories by 447.8% during the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company's stock valued at $41,000 after buying an additional 2,230 shares during the last quarter. Institutional investors own 3.85% of the company's stock.
Dr. Reddy's Laboratories Trading Down 6.6 %
RDY stock traded down $0.87 during mid-day trading on Friday, reaching $12.37. 3,932,444 shares of the stock traded hands, compared to its average volume of 1,348,794. Dr. Reddy's Laboratories Limited has a one year low of $12.36 and a one year high of $16.89. The stock has a market capitalization of $10.32 billion, a PE ratio of 19.69 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The business has a 50-day moving average price of $13.33 and a two-hundred day moving average price of $14.50.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Equities research analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the company. Nomura downgraded Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th. StockNews.com downgraded shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th.
Get Our Latest Stock Analysis on Dr. Reddy's Laboratories
About Dr. Reddy's Laboratories
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
See Also
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
